Study on Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

Overview of Ovarian Cancer

Ovarian cancer ranks as the fourth leading cause of cancer-related deaths among women in the United States, highlighting its aggressive nature. Unfortunately, most diagnoses occur at advanced stages due to the absence of reliable early symptoms or effective screening tests. Among the four types of ovarian cancer, epithelial ovarian cancer is the most prevalent.

Current Treatment Guidelines

According to American cancer treatment guidelines, only patients with advanced ovarian cancer who are ineligible for primary surgery due to unacceptable surgical risks are recommended for neoadjuvant chemotherapy (NACT).

Understanding Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy involves administering drug treatment before the surgical removal of a tumor, contrasting with conventional methods where chemotherapy begins post-surgery. Between 2011 and 2012, certain regions in the United States witnessed a nearly 25% increase in the adoption of NACT for advanced ovarian cancer patients.

Research Study Findings

Study Overview

Researchers published a study in The British Medical Journal, analyzing data from the National Cancer Database, which encompassed information from over 1,500 hospitals across the United States. The primary objective was to assess whether the increased use of neoadjuvant chemotherapy could lead to reduced mortality rates within three years of tumor diagnosis.

Data Collection and Regions Analyzed

The study focused on women with advanced ovarian cancer (stages 3C and 4) treated between 2011 and 2012, specifically in five census divisions. Two of these divisions, New England and East South Central, experienced a significant uptick in NACT adoption, while the other three—South Atlantic, East North Central, and West North Central—served as control regions with minimal changes in NACT usage during the same period.

Mortality Rate Comparisons

The researchers found that women diagnosed in 2012 in the regions with heightened NACT adoption had a 41% higher likelihood of receiving this treatment compared to those diagnosed in earlier years. In contrast, no such difference was observed in the control regions. A total of 1,157 women received treatment in the two regions with increased NACT, compared to 4,878 in the control regions.

Patients treated in 2012 in New England and East South Central experienced a lower risk of mortality from all causes. Conversely, the mortality risk for those in the control regions remained consistent with previous years. Notably, the mortality reduction in the New England and East South Central divisions was significantly greater than the static rates in the control regions.

30-Day and 90-Day Post-Surgery Mortality Rates

The percentage of women who died within 30 days of tumor extraction surgery dropped from 3.1% to 1.8% in the New England and East South Central divisions between 2011 and 2012. In comparison, the control regions reported 1.9% and 2.2% mortality rates, respectively. Additionally, 90-day post-operative mortality decreased from 7% to 4.4% in the regions with NACT adoption, while the control regions showed a minimal reduction from 5% to 4.3%.

Future Considerations

Interestingly, two of the three control regions increased their utilization of NACT in 2013, which was later linked to improved survival outcomes. However, the authors caution that their findings are based on data from the National Cancer Database, which only captures approximately 70% of cancer patients in the U.S. Therefore, the results may not fully represent the remaining 30% of advanced ovarian cancer patients.

Implications of Neoadjuvant Chemotherapy

Potential Benefits and Limitations

The study’s findings indicate that the increased use of neoadjuvant chemotherapy can lead to a reduction in mortality rates within three years of diagnosis, potentially influencing physicians and policymakers to consider NACT for patients with advanced ovarian cancer. Nonetheless, the authors emphasize that not all patients will benefit equally from this treatment, as the most significant positive associations were noted among older patients and those with stage 4 cancer. Further research is essential to pinpoint which patients are most likely to gain from neoadjuvant chemotherapy.

References

(1) Melamed A, Fink G, Wright A A, Keating N L, Gockley A A, del Carmen M G, Schorge J O, Rauh-Hain J A. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all-cause mortality: quasi-experimental study. The BMJ 2018; 360: 1-8.
(2) Green, A. (2016, January 28). Ovarian Cancer (Cancer of the Ovaries). Retrieved from https://www.medicinenet.com/ovarian_cancer/article.htm#ovarian_cancer_facts
(3) Neoadjuvant Chemotherapy. Retrieved from http://chemoth.com/neoadjuvant-chemotherapy